Vaishali Pharma (VAISHALI) Q4 24/25 earnings summary

Executive summary

• Audited financial results for the year ended March 31, 2025, were approved by the Board on May 28, 2025.

• The audit opinion is qualified due to material uncertainty regarding recoverability of significant trade receivables, deposits, loans, and advances.

Financial highlights

• Revenue from operations for FY25 was ₹9,788.20 lakh, up from ₹8,176.35 lakh year-over-year.

• Net profit for FY25 was ₹81.73 lakh, compared to ₹71.89 lakh in FY24.

• Total comprehensive income for FY25 was ₹82.02 lakh.

• Basic and diluted EPS for FY25 were ₹0.31 and ₹0.31, respectively.

Outlook and guidance

• The auditor highlighted material uncertainty regarding the recoverability of certain receivables and advances, which may impact future results.